Ligand Pharmaceuticals | LGND - Cash And Equivalent


Ligand Pharmaceuticals reported $664.52M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Agenus USD 3.46M 6.08M Sep/2025
Amgen USD 9.13B 316M Dec/2025
Anika Therapeutics USD 57.99M 4.82M Sep/2025
Arrowhead Research USD 201.64M 112.94M Dec/2025
Baxter International USD 1.97B 240M Dec/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Enanta Pharmaceuticals USD 37.44M 5.14M Dec/2025
Enviri Corporation USD 115.36M 17.56M Sep/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Glaxosmithkline GBP 3.3B 303M Sep/2025
Heron Therapeutics USD 43.07M 26.55M Sep/2025
Insmed USD 510.44M 175.68M Dec/2025
Intrexon USD 9.34M 1.77M Jun/2024
Ionis Pharmaceuticals USD 2.68B 437M Dec/2025
Karyopharm Therapeutics USD 37.67M 1.05M Sep/2025
Ligand Pharmaceuticals USD 664.52M 596.85M Sep/2025
MacroGenics USD 80.13M 50.56M Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Pacira USD 158.54M 10.96M Dec/2025
Pfizer USD 1.34B 295M Sep/2025
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Veracyte USD 362.58M 47M Dec/2025